Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease.
Features of Parkinson's disease (PD) include oxidative stress, nigral mitochondrial complex I deficiency and visual dysfunction, all of which are also associated with coenzyme Q(10) (CoQ(10)) deficiency. The objective of this monocenter, parallel group, placebo controlled, double-blind trial was to determine the symptomatic response of daily oral application of 360 mg CoQ(10) lasting 4 weeks on scored PD symptoms and visual function, measured with the Farnsworth-Munsell 100 Hue test (FMT), in 28 treated and stable PD patients. CoQ(10) supplementation provided a significant (P=0.01) mild symptomatic benefit on PD symptoms and a significantly (F((1,24))=8.48, P=0.008) better improvement of FMT performance compared with placebo. Our results indicate a moderate beneficial effect of oral CoQ(10) supplementation in PD patients.
Müller
Thomas
T
Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, Germany. thomas.mueller@ruhr-uni-bochum.de
Büttner
Thomas
T
Gholipour
Ali Farshad
AF
Kuhn
Wilfried
W
D000368:Aged; D000704:Analysis of Variance; D003067:Coenzymes; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D003067:Coenzymes; D014451:Ubiquinone; C024989:coenzyme Q10